Costs of Care and Adherence to Treatment for Cystic Fibrosis (COMURA MUCOBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02832479
Recruitment Status : Completed
First Posted : July 14, 2016
Last Update Posted : August 10, 2016
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:
Evolution of medical care for patients with cystic fibrosis appeared in recent years: prolongation of life expectancy with consequently increased comorbidities and the use of lung transplantation, systematic neonatal screening of new born since 2002, prescription of expensive new molecules or new presentation. This evolution justifies to realize an update of statistics of costs of care and to assess adherence to treatment

Condition or disease
Cystic Fibrosis

Study Type : Observational
Actual Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Costs of Care and Adherence to Treatment for Cystic Fibrosis.
Study Start Date : October 2014
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Primary Outcome Measures :
  1. treatment cost [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. adherence rate for chronic treatment [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with cystic fibrosis living in Rhône-Alpes region

Inclusion Criteria:

  • Patients with cystic fibrosis,
  • Followed by one of the cystic fibrosis center of the Rhône-Alpes region (pediatric and adult of Lyon and Grenoble)
  • Affiliated to the general scheme of health insurance,
  • And domiciled in the Rhône-Alpes region.

Exclusion Criteria:

  • Transplanted patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02832479

Hospices civils de Lyon, centre hospitalier lyon Sud
Pierre Benite, France, 69310
Sponsors and Collaborators
Hospices Civils de Lyon

Responsible Party: Hospices Civils de Lyon Identifier: NCT02832479     History of Changes
Other Study ID Numbers: 69HCL15_0698
First Posted: July 14, 2016    Key Record Dates
Last Update Posted: August 10, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases